Iziphumo Ezimangalisayo Zonyango lwe-CAR-T olujoliswe kwi-CD7 lwe-T-ALL kunye ne-T-LBL

Uvavanyo lweklinikhi lwakutshanje lubonise inkqubela phambili ebalulekileyo kunyango lwe-T-cell acute lymphoblastic leukemia (T-ALL) ephinde yabuyela kwisimo sayo okanye enganyangekiyo kunye ne-T-cell lymphoblastic lymphoma (T-LBL) kusetyenziswa unyango lwe-CD7-targetted chimeric antigen receptor (CAR) T cell. Olu phononongo, olwenziwe liqela elivela kwiSibhedlele iHebei Yanda Lu Daopei kunye neLu Daopei Institute of Hematology, lubandakanye izigulana ezingama-60 ezifumene idosi enye yeeseli ze-anti-CD7 CAR (NS7CAR) T ezikhethiweyo ngokwendalo.

Iziphumo zovavanyo ziyakhuthaza kakhulu. Ngomhla wama-28, ama-94.4% ezigulana afumene uxolelo olupheleleyo olupheleleyo (CR) kwithambo lomnkantsha. Ukongeza, phakathi kwezigulana ezingama-32 ezinesifo esingaphandle kwe-medullary, ama-78.1% abonise impendulo entle, apho ama-56.3% afumene uxolelo olupheleleyo kunye nama-21.9% afumene uxolelo olupheleleyo. Amanqanaba okusinda kweminyaka emibini iyonke kunye nokusinda okungenankqubela phambili yayingama-63.5% kunye nama-53.7%, ngokulandelelana.

Olu nyango lutsha luphawuleka ngeprofayili yalo yokhuseleko olulawulekayo, apho i-cytokine release syndrome isenzeka kwi-91.7% yezigulane (uninzi lwazo lukwibanga le-1/2), kwaye ubuthi be-neurotoxicity bubonwe kwi-5% yamatyala. Ngaphezu koko, uphando lufumanise ukuba izigulane eziqhubekile nokufakelwa i-consolidation emva kokufikelela kwi-CR zazinezinga eliphezulu lokusinda ezingenankqubela phambili xa kuthelekiswa nezo zingazange ziphumelele.

Inkampani yethu ikwahlola amandla onyango lweeseli ze-CD7 CAR-T ngemveliso yethu, ejolise ekuncediseni ekuphuculeni unyango lwe-T-cell monoancies.

Ezi ziphumo zigxininisa amandla onyango lweeseli zeCAR-T ezijoliswe kwi-CD7 ukunika ithemba elitsha kwizigulane ezine-T-ALL kunye ne-T-LBL ezinganyangekiyo okanye eziphinde zabuyela kwisifo, nto leyo ebonisa isiganeko esibalulekileyo kumlo oqhubekayo nxamnye nezi zifo zinzima.